Starling Oncology insider buys 12K shares at $6.54
Starling Oncology, Inc. insider Jorey Chernett, a more-than-10% owner, reported mixed transactions in company securities.
Rhea-AI Filing Summary
Starling Oncology, Inc. insider Jorey Chernett, a more-than-10% owner, reported mixed transactions in company securities. On 2026-08-14, Chernett purchased 12,000 shares of common stock at $6.54 per share, bringing direct holdings to 10,660,858 shares. On 2026-08-13, Chernett sold 100 call option contracts on Starling Oncology (each linked to 100 shares, or 10,000 underlying common shares) with a $9.00 exercise price and 19-Feb-2027 expiration, at $6.24 per option. According to a footnote, this option sale is treated as a matchable transaction under Section 16(b), and Chernett intends to disgorge the calculated short-swing profit to the issuer.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 12,000 | $6.54 | $78K |
| Sale | Call Option (STLN 19FEB27 $9C) F1 | 100 | $6.24 | $624.00 |
Footnotes (1)
- F1. The sale of these call options is a matchable transaction subject to Section 16(b) of the Securities Exchange Act of 1934. The reporting person has calculated a short-swing profit in connection with such matchable transactions, which the reporting person intends to disgorge to the Issuer.
Key Figures
Key Terms
Section 16(b) regulatory
short-swing profit regulatory
disgorge regulatory
call options financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did STLN insider Jorey Chernett buy in this Form 4 filing?
What options on STLN did Jorey Chernett sell in this Form 4?
What is the significance of Section 16(b) in this STLN Form 4 filing?
Is the overall trading activity by STLN insider Chernett net buying or selling?
AI-generated analysis. How Rhea-AI works. Not financial advice.